Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 14/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 5/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2520710 | 0.89 | FFAR1 (0.53) | FFAR1CYP2C8CYP2C9 | |
| SCHEMBL1666790 | 0.89 | FFAR1 (0.53) | FFAR1CYP2C8CYP2C9 | |
| SCHEMBL14871759 | 0.89 | FFAR1 (0.53) | FFAR1CYP2C8CYP2C9 | |
| SCHEMBL1666789 | 0.89 | FFAR1 (0.53) | FFAR1CYP2C8CYP2C9 | |
| Hydrochloric Acid SCHEMBL2517566 | 0.87 | FFAR1 (0.52) | FFAR1CYP2C8CYP2C9 | |
| Hydrochloric Acid SCHEMBL2517563 | 0.87 | FFAR1 (0.52) | FFAR1CYP2C8CYP2C9 | |
| SCHEMBL15397536 | 0.80 | FFAR1 (0.42) | FFAR1CYP2C8CYP2C9 | |
| SCHEMBL2521957 | 0.79 | FFAR1 (0.42) | FFAR1CYP2C8CYP2C9 | |
| SCHEMBL1666779 | 0.79 | FFAR1 (0.42) | FFAR1CYP2C8CYP2C9 | |
| SCHEMBL1666781 | 0.79 | FFAR1 (0.42) | FFAR1CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017525-A1 | CYCLOBUTYL PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-01-20 | — | — | US | disclosed |
| WO-2020123271-A1 | CYCLOBUTYL PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017525-A1 | CYCLOBUTYL PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | PDE9A, PDE5A, PDE3B | FFAR1 3388/4885CYP2C8 1706/4885CYP2C9 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.